Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

UK Health Body Approves Novartis's Tasigna For CML

share with twitter share with LinkedIn share with facebook
share via e-mail
04/25/2012 | 01:16am CEST

The U.K.'s health-cost regulator has decided to back an expensive cancer drug from Novartis AG (NVS) for treating chronic myeloid leukemia--but not one from U.S.-based Bristol-Myers Squibb Co. (BMY)--after the Swiss drug maker offered to cut the drug's price.

The independent National Institute for Clinical Excellence, known by its acronym NICE, said Wednesday it approved Novartis's Tasigna and the company's older drug, whose brand name is Glivec, for use in treating CML on the publicly funded National Health Service. The generic names for Tasigna and Glivec are nilotinib and imatinib, respectively.

However, NICE said it wasn't approving Bristol-Myers Squibb's Sprycel, also known as dasatinib.

CML is a cancer of blood-forming cells in the bone marrow that usually develops slowly, which is why it is described as a chronic form of the disease.

NICE director Carole Longson said: "The recommendations reaffirm the use of imatinib as an effective treatment for the majority of patients and a cost-effective use of NHS resources, and we are also very pleased to be able to add a further treatment option for these patients by recommending nilotinib.

"Although no trials directly comparing dasatinib and nilotinib were available, the committee concluded from indirect comparisons that dasatinib and nilotinib could be considered equally as effective in treating CML.

"However, the manufacturer of nilotinib has already agreed with the Department of Health to provide the drug to the NHS at a discounted price. This reduction in cost enabled the independent committee to approve nilotinib for use on the NHS."

Dasatinib and nilotinib both cost over GBP30,000 per patient a year and the standard dose of imatinib costs GBP20,000.

NICE didn't disclose the price discount offered by Novartis for nilotinib.

-By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; [email protected]

Stocks mentioned in the article
ChangeLast1st jan.
BRISTOL-MYERS SQUIBB COMPANY 0.15% 52.77 Delayed Quote.-14.02%
NOVARTIS -0.13% 75.56 Delayed Quote.-8.30%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on NOVARTIS
05/26NOVARTIS : European Commission approves Sandoz`s Zessly to treat gastroenterolog..
05/26GLOBAL ACTIVE PHARMACEUTICAL INGREDI : Pfizer, Inc., Novartis International AG, ..
05/25NOVARTIS : Patent Issued for Surgical Guidance and Planning Software for Astigma..
05/25NOVARTIS : Patent Issued for Ophthalmic Illumination Systems, Devices, and Metho..
05/25NOVARTIS : Patent Issued for Ophthalmic Lens Having an Extended Depth of Focus (..
05/25NOVARTIS : announces FDA approval of Gilenya® as the first disease-modifying the..
05/25FINDINGS IN THE AREA OF ONCOLOGY REP : a platform of basket trials)
05/25NOVARTIS` : Sandoz scores EU approval for Remicade biosimilar
05/25NOVARTIS : Sandoz receives European Commission approval for Zessly in gastroente..
05/25JOHNSON & JOHNSON : EU nod for Sandoz Remicade biosimilar Zessly
More news
News from SeekingAlpha
08:00a3 THINGS IN BIOTECH, MAY 26 : Immunotherapy Strikes Lung Cancer Yet Again 
05/25ROUNDS REPORT : CryoPort Rallied While The FDA Approved Palynziq 
05/25Magenta Therapeutics on deck for IPO 
05/25Premarket analyst action - healthcare 
05/24'Safer' Dividend Healthcare Top WallStar Gainers Are Gilead, Sanofi, Amerisou.. 
Financials ($)
Sales 2018 52 599 M
EBIT 2018 13 274 M
Net income 2018 9 218 M
Debt 2018 13 550 M
Yield 2018 3,89%
P/E ratio 2018 15,81
P/E ratio 2019 18,75
EV / Sales 2018 3,95x
EV / Sales 2019 3,80x
Capitalization 194 B
Duration : Period :
Novartis Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 90,6 $
Spread / Average Target 19%
EPS Revisions
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Srikant Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS-8.30%194 397
JOHNSON & JOHNSON-11.45%325 801
PFIZER-0.91%208 713
ROCHE HOLDING LTD.-9.17%189 708
AMGEN2.33%117 942